ATE506439T1 - Codon-optimisierte hiv-rt-nef-gag dna impfstoffe - Google Patents

Codon-optimisierte hiv-rt-nef-gag dna impfstoffe

Info

Publication number
ATE506439T1
ATE506439T1 AT02798748T AT02798748T ATE506439T1 AT E506439 T1 ATE506439 T1 AT E506439T1 AT 02798748 T AT02798748 T AT 02798748T AT 02798748 T AT02798748 T AT 02798748T AT E506439 T1 ATE506439 T1 AT E506439T1
Authority
AT
Austria
Prior art keywords
nef
codone
fragment
dna vaccines
hiv
Prior art date
Application number
AT02798748T
Other languages
English (en)
Inventor
Andrew Beaton
Peter Ertl
Gerald Gough
Andrew Lear
John Tite
Wely Catherine Van
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority claimed from PCT/EP2002/010592 external-priority patent/WO2003025003A2/en
Application granted granted Critical
Publication of ATE506439T1 publication Critical patent/ATE506439T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02798748T 2001-09-20 2002-09-18 Codon-optimisierte hiv-rt-nef-gag dna impfstoffe ATE506439T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines
PCT/EP2002/010592 WO2003025003A2 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines

Publications (1)

Publication Number Publication Date
ATE506439T1 true ATE506439T1 (de) 2011-05-15

Family

ID=43927344

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02798748T ATE506439T1 (de) 2001-09-20 2002-09-18 Codon-optimisierte hiv-rt-nef-gag dna impfstoffe

Country Status (7)

Country Link
KR (1) KR101067231B1 (de)
AT (1) ATE506439T1 (de)
DE (1) DE60239815D1 (de)
HK (1) HK1066830A1 (de)
MY (1) MY131949A (de)
TW (1) TWI329647B (de)
ZA (1) ZA200402189B (de)

Also Published As

Publication number Publication date
DE60239815D1 (de) 2011-06-01
KR101067231B1 (ko) 2011-09-22
TWI329647B (en) 2010-09-01
MY131949A (en) 2007-09-28
ZA200402189B (en) 2005-07-27
KR20040039387A (ko) 2004-05-10
HK1066830A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO991078D0 (no) HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV
DE69941049D1 (de) Retrovirales verabreichungssystem
DK0640133T3 (da) Rekombinante DNA-molekyler, der koder for aminopeptidaseenzymer og deres anvendelse i fremstillingen af vacciner mod helmin
ATE420183T1 (de) Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv
TW200502245A (en) Vaccine
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE506439T1 (de) Codon-optimisierte hiv-rt-nef-gag dna impfstoffe
ATE370160T1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
WO2003052122A3 (en) Gp41 inhibitor
DE60313743D1 (de) Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen
WO2002022663A3 (en) Stress resistant retroviruses
DE10393824D2 (de) Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
ATE456659T1 (de) Streptococcus pyogenes polypeptide und entsprechende dna fragmente
DE60229966D1 (de) Diabetesmodell
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
DE69937900D1 (de) Avipox-vektor, der für ein hiv-antigen und gamma-interferon kodiert.
DE60133455D1 (de) G-protein gekoppelter rezeptor
HUP0200832A2 (hu) Babesia canis oltóanyag
YU71803A (sh) Monoklonalno antitelo specifično za epitop glikoproteina kodiran od strane inaktivirane mačije imunodeficijencije
MX2024002010A (es) Vacunas terapeuticas contra el virus del papiloma.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties